29 related articles for article (PubMed ID: 15848570)
1. Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis.
Papadimitriou TI; van Caam A; van der Kraan PM; Thurlings RM
Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203525
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 2 receptor antagonists for kidney transplant recipients.
Webster AC; Ruster LP; McGee R; Matheson SL; Higgins GY; Willis NS; Chapman JR; Craig JC
Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD003897. PubMed ID: 20091551
[TBL] [Abstract][Full Text] [Related]
3. The role of basiliximab in the evolving renal transplantation immunosuppression protocol.
Salis P; Caccamo C; Verzaro R; Gruttadauria S; Artero M
Biologics; 2008 Jun; 2(2):175-88. PubMed ID: 19707352
[TBL] [Abstract][Full Text] [Related]
4. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
[TBL] [Abstract][Full Text] [Related]
5. Open-label, multicenter study on the safety, tolerability, and efficacy of Simulect in pediatric renal transplant recipients receiving triple therapy with cyclosporin, mycophenolate, and corticosteroids.
Turconi A; Rilo LR; Goldberg J; de Boccardo G; Garsd A; Otero A
Transplant Proc; 2005 Mar; 37(2):672-4. PubMed ID: 15848497
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
[TBL] [Abstract][Full Text] [Related]
7. Basiliximab (Simulect) in acute tubular necrosis high-risk kidney transplantation.
Rivera CF; Hernández AA; Verdejo PV; García JO; Rego SC; Cañedo FV
Transplant Proc; 2005 Nov; 37(9):3733-5. PubMed ID: 16386521
[TBL] [Abstract][Full Text] [Related]
8. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
Sollinger H; Kaplan B; Pescovitz MD; Philosophe B; Roza A; Brayman K; Somberg K
Transplantation; 2001 Dec; 72(12):1915-9. PubMed ID: 11773888
[TBL] [Abstract][Full Text] [Related]
9. Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients.
Tan J; Yang S; Wu W
Transplant Proc; 2005 Mar; 37(2):903-5. PubMed ID: 15848570
[TBL] [Abstract][Full Text] [Related]
10. Basiliximab: a review of its use as induction therapy in renal transplantation.
Chapman TM; Keating GM
Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
[TBL] [Abstract][Full Text] [Related]
11. Basiliximab: a review of its use as induction therapy in renal transplantation.
McKeage K; McCormack PL
BioDrugs; 2010 Feb; 24(1):55-76. PubMed ID: 20055533
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of basiliximab in kidney transplantation.
Boggi U; Vistoli F; Signori S; Del Chiaro M; Amorese G; Barsotti M; Rizzo G; Marchetti P; Danesi R; Del Tacca M; Mosca F
Expert Opin Drug Saf; 2005 May; 4(3):473-90. PubMed ID: 15934854
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
